Home » Stocks » GANX

Gain Therapeutics, Inc. (GANX)

Gain Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) 28,881
Net Income (ttm) -3.58M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News
NASDAQ - 6 days ago

Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, filed on Friday with the SEC to raise up to $40 million in an initial public offer...

SEC - 6 days ago

Gain Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

About GANX

Gain Therapeutics is a development stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”), including rare genetic diseases and neurological disorders. We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treatin... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Pending
CEO
Eric I. Richman
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
GANX
Full Company Profile

Financial Performance

In 2020, GANX's revenue was $28,881, a decrease of -30.07% compared to the previous year's $41,301. Losses were -$3.58 million, 63.1% more than in 2019.

Financial Statements